Jhih-Yu Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jhih-Yu Chen has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Aakash M Rao
1 shared publication- Adithya Cattamanchi
Center for Tuberculosis, Institute for Global Health Sciences, University of California San Francisco , San Francisco, California
1 shared publication Akanksha Arora
1 shared publication- Albert Li
Institute for Pharmacy and Molecular Biotechnology, Heidelberg University and BioQuant, Heidelberg, Germany
1 shared publication Aniket Gupta
1 shared publicationAshwin Salampuria
1 shared publication
Latest Publications
- Open Access
- 16 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10)
Accelerating Cough-Based Algorithms for Pulmonary Tuberculosis Screening: Results From the CODA TB DREAM Challenge
Background: Open-access data challenges can accelerate innovation in artificial intelligence–based tools. In the Cough Diagnostic Algorithm for Tuberculosis (CODA TB) DREAM Challenge, we developed and independently validated cough sound–based artificial intelligence algorithms for tuberculosis screening. Methods: We included data from 2143 adults with ≥2 weeks of cough from outpatient clinics in India, Madagascar, the Philippines, South Africa, Tanzania, Uganda, and Vietnam. A standard tuberculosis evaluation was completed, and ≥3 solicited coughs were recorded using a smartphone. We invited teams to develop models using training data to classify microbiologically confirmed tuberculosis disease using (1) cough sound features only and/or (2) cough sound features with routinely available clinical data. After 4 months, they submitted the algorithms for independent test set validation. Models were ranked by area under the receiver operating characteristic curve (AUROC) and partial AUROC (pAUROC) to achieve at least 80% sensitivity and 60% specificity. Results: Eleven cough models and 6 cough-plus-clinical models were submitted. AUROCs for cough models ranged from 0.69 to 0.74, and the highest performing model achieved 55.5% specificity (95% confidence interval, 47.7%–64.2%) at 80% sensitivity. The addition of clinical data improved AUROCs (range, 0.78–0.83); 5 of the 6 models reached the target pAUROC, and the highest performing model had 73.8% specificity (95% confidence interval, 60.8%–80.0%) at 80% sensitivity. The AUROC varied by country and was higher among male and human immunodeficiency virus–negative individuals. Conclusions: In a short period, an open-access data challenge facilitated the development of new cough-based tuberculosis algorithms and demonstrated potential as a tuberculosis screening tool.
- 16 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10)
Open AccessAccelerating Cough-Based Algorithms for Pulmonary Tuberculosis Screening: Results From the CODA TB DREAM Challenge
Background: Open-access data challenges can accelerate innovation in artificial intelligence–based tools. In the Cough Diagnostic Algorithm for Tuberculosis (CODA TB) DREAM Challenge, we developed and independently validated cough sound–based artificial intelligence algorithms for tuberculosis screening. Methods: We included data from 2143 adults with ≥2 weeks of cough from outpatient clinics in India, Madagascar, the Philippines, South Africa, Tanzania, Uganda, and Vietnam. A standard tuberculosis evaluation was completed, and ≥3 solicited coughs were recorded using a smartphone. We invited teams to develop models using training data to classify microbiologically confirmed tuberculosis disease using (1) cough sound features only and/or (2) cough sound features with routinely available clinical data. After 4 months, they submitted the algorithms for independent test set validation. Models were ranked by area under the receiver operating characteristic curve (AUROC) and partial AUROC (pAUROC) to achieve at least 80% sensitivity and 60% specificity. Results: Eleven cough models and 6 cough-plus-clinical models were submitted. AUROCs for cough models ranged from 0.69 to 0.74, and the highest performing model achieved 55.5% specificity (95% confidence interval, 47.7%–64.2%) at 80% sensitivity. The addition of clinical data improved AUROCs (range, 0.78–0.83); 5 of the 6 models reached the target pAUROC, and the highest performing model had 73.8% specificity (95% confidence interval, 60.8%–80.0%) at 80% sensitivity. The AUROC varied by country and was higher among male and human immunodeficiency virus–negative individuals. Conclusions: In a short period, an open-access data challenge facilitated the development of new cough-based tuberculosis algorithms and demonstrated potential as a tuberculosis screening tool.
- Open Access
- 30 April 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 971
A Single-Cell Network-Based Drug Repositioning Strategy for Post-COVID-19 Pulmonary Fibrosis
Post-COVID-19 pulmonary fibrosis (PCPF) is a long-term complication that appears in some COVID-19 survivors. However, there are currently limited options for treating PCPF patients. To address this problem, we investigated COVID-19 patients’ transcriptome at single-cell resolution and combined biological network analyses to repurpose the drugs treating PCPF. We revealed a novel gene signature of PCPF. The signature is functionally associated with the viral infection and lung fibrosis. Further, the signature has good performance in diagnosing and assessing pulmonary fibrosis. Next, we applied a network-based drug repurposing method to explore novel treatments for PCPF. By quantifying the proximity between the drug targets and the signature in the interactome, we identified several potential candidates and provided a drug list ranked by their proximity. Taken together, we revealed a novel gene expression signature as a theragnostic biomarker for PCPF by integrating different computational approaches. Moreover, we showed that network-based proximity could be used as a framework to repurpose drugs for PCPF.
- 30 April 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (5) , 971
Open AccessA Single-Cell Network-Based Drug Repositioning Strategy for Post-COVID-19 Pulmonary Fibrosis
Post-COVID-19 pulmonary fibrosis (PCPF) is a long-term complication that appears in some COVID-19 survivors. However, there are currently limited options for treating PCPF patients. To address this problem, we investigated COVID-19 patients’ transcriptome at single-cell resolution and combined biological network analyses to repurpose the drugs treating PCPF. We revealed a novel gene signature of PCPF. The signature is functionally associated with the viral infection and lung fibrosis. Further, the signature has good performance in diagnosing and assessing pulmonary fibrosis. Next, we applied a network-based drug repurposing method to explore novel treatments for PCPF. By quantifying the proximity between the drug targets and the signature in the interactome, we identified several potential candidates and provided a drug list ranked by their proximity. Taken together, we revealed a novel gene expression signature as a theragnostic biomarker for PCPF by integrating different computational approaches. Moreover, we showed that network-based proximity could be used as a framework to repurpose drugs for PCPF.